PHASE II STUDY OF EVEROLIMUS IN PATIENTS WITH THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY

Trial Profile

PHASE II STUDY OF EVEROLIMUS IN PATIENTS WITH THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Malignant thymoma; Thymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Dec 2017 Primary endpoint has been met. (disease control rate), as per an article published in the Journal of Clinical Oncology.
    • 14 Dec 2017 Results published in the Journal of Clinical Oncology
    • 31 Oct 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top